(CercleFinance.com) – Eurobio Scientific announces the signing of an agreement to acquire all rights to the second-generation gene expression test for breast cancer EndoPredict from Myriad Genetics.
Following this acquisition, Eurobio Scientific will license Myriad Genetics to manufacture, sell and distribute the EndoPredict breast cancer screening test for laboratory developed tests (LDTs) primarily performed in the United States.
Additionally, Myriad Genetics will license Eurobio Scientific to manufacture, sell and distribute the Prolaris prostate cancer screening test kit. The completion of the operation is scheduled for next July.